ALTERITY THERAPEUTICS LTD (ATHE) Form 6-K — Oct 21, 2026
Alterity Therapeutics announced changes to CEO and Managing Director Dr David Stamler's remuneration package, effective 15 October 2026, following a board review against market comparables. The revised package includes a US$525,000 base salary, a short-term incentive of up to 100% of base salary, a 6-month notice period, and severance terms including one year of salary plus medical coverage on termination without cause. Change-of-control provisions accelerate 100% of unvested equity awards, and the company will seek shareholder approval at its upcoming AGM for the termination benefits, as required under ASX Listing Rule 3.16.4.
Key figures
- Base salary
- US$525,000 per annum
- Notice period
- 6 months
- Short term incentive
- Up to 100% of annualised base salary
- Severance without cause
- 100% of annual base salary plus 12 months medical premiums
- Change of control resignation severance
- 1x annual base salary plus target bonus
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.